Jasbir Seehra - 16 Feb 2023 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Role
Chief Executive Officer, Director
Signature
/s/ Keith Regnante, Attorney-in-Fact
Issuer symbol
KROS
Transactions as of
16 Feb 2023
Transactions value $
$0
Form type
4
Filing time
17 Feb 2023, 15:13:56
Previous filing
17 Jun 2022
Next filing
11 Apr 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KROS Employee Stock Option (right to buy) Award $0 +200K $0.00 200K 16 Feb 2023 Common Stock 200K $54.38 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option shall vest on February 16, 2024, and 6.25% of the shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.